KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) FCF Margin (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of FCF Margin data on record, last reported at 52.39% in Q4 2025.

  • For Q4 2025, FCF Margin rose 10436.0% year-over-year to 52.39%; the TTM value through Dec 2025 reached 22.75%, up 1848.0%, while the annual FY2025 figure was 22.75%, 1932.0% up from the prior year.
  • FCF Margin reached 52.39% in Q4 2025 per EBS's latest filing, up from 1.04% in the prior quarter.
  • Across five years, FCF Margin topped out at 85.8% in Q2 2024 and bottomed at 121.18% in Q1 2023.
  • Average FCF Margin over 5 years is 3.39%, with a median of 2.44% recorded in 2025.
  • Peak YoY movement for FCF Margin: crashed -10787bps in 2022, then surged 11747bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 44.85% in 2021, then rose by 19bps to 53.18% in 2022, then tumbled by -86bps to 7.48% in 2023, then crashed by -795bps to 51.98% in 2024, then skyrocketed by 201bps to 52.39% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 52.39% in Q4 2025, 1.04% in Q3 2025, and 71.97% in Q2 2025.